Swiss Insurance Stock News

Recently, Relation Therapeutics announced a multi-program collaboration with Novartis in immuno-dermatology, combining US$55 million of upfront, equity and R&D funding with up to US$1.70 billion in potential milestones and royalties, alongside Novartis’s latest US FDA approval for Itvisma and strong Phase III trial results in immune thrombocytopenia and breast cancer. Together, these developments spotlight how Novartis is pairing AI-enabled target discovery with late-stage pipeline execution...

There wouldn't be many who think Sulzer Ltd's ( VTX:SUN ) price-to-earnings (or "P/E") ratio of 17.5x is worth a...

What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...

What are the early trends we should look for to identify a stock that could multiply in value over the long term? In a...

It is doubtless a positive to see that the Bellevue Group AG ( VTX:BBN ) share price has gained some 37% in the last...

If you are wondering whether Nestlé is quietly becoming good value again, or if it is still priced for safety rather than upside, you are not alone. Plenty of long term investors are asking the same question. The stock is up 4.9% year to date and 7.3% over the last year, but those gains sit against a 21.5% slide over 3 years and a 9.5% drop over 5 years, suggesting the market is still recalibrating its expectations. Recent months have seen Nestlé in the headlines for portfolio reshaping and...

Newron Pharmaceuticals has initiated its ENIGMA-TRS 2 global Phase III trial of evenamide as an add-on therapy for treatment-resistant schizophrenia, following US FDA and IRB approvals, with the first site at UCLA’s Semel Translational Research Center for Neuropsychiatry. The study’s focus on rigorously defined treatment-resistant patients and evenamide’s targeted sodium-channel mechanism highlights its potential differentiation from existing antipsychotic options. Next, we’ll explore how...

As European markets show mixed returns with the STOXX Europe 600 Index inching higher on hopes of interest rate cuts, investors are keenly observing economic indicators such as inflation and GDP revisions. In this environment, identifying undervalued stocks can be a strategic move, as these equities may offer potential for growth when market conditions stabilize.

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Vetropack Holding AG's ( VTX:VETN ) price-to-earnings (or "P/E") ratio of 28.5x might make it look like a sell right...

Sika (SWX:SIKA) just pulled back the curtain on its Fast Forward program, a multi year push to digitize its value chain, streamline operations, and reshape its footprint, especially in China. See our latest analysis for Sika. The Fast Forward announcement lands after a tough stretch, with the share price down sharply on a year to date basis and the one year total shareholder return also deeply negative. This suggests sentiment has cooled even as management signals a profitability reset. If...

It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...

Cosmo Pharmaceuticals has reported strong top-line Phase III results for clascoterone 5% topical solution in male androgenetic alopecia and, together with Glenmark Pharmaceuticals, secured European Commission marketing authorization for Winlevi (clascoterone 10 mg/g cream) to treat acne vulgaris in 17 countries. These developments highlight clascoterone’s potential as a versatile, first-in-class topical androgen receptor inhibitor across both hair loss and acne, expanding Cosmo’s...

Adecco Group (SWX:ADEN) has been drifting lower over the past month, and that quiet slide is exactly why the stock is interesting now, especially given its improving earnings backdrop and deep valuation discount. See our latest analysis for Adecco Group. At around CHF 21.96 per share, Adecco’s roughly 6 percent 3 month share price decline contrasts with stabilising year to date performance, while a 5 year total shareholder return near minus 48 percent shows how heavily sentiment has reset...

The Cosmo Pharmaceuticals N.V. ( VTX:COPN ) share price has done very well over the last month, posting an excellent...

When you see that almost half of the companies in the Machinery industry in Switzerland have price-to-sales ratios (or...

Cosmo Pharmaceuticals (SWX:COPN) is back on investor radar after two key catalysts: strong Phase III data for its Clascoterone 5% male hair loss treatment and European approval of Winlevi for acne across 17 countries. See our latest analysis for Cosmo Pharmaceuticals. The market has taken notice, with the share price jumping to about CHF 78.3 and a strong 1 day share price return of roughly 19 percent, reinforcing an already solid one year total shareholder return near 30 percent and...

Julius Baer Gruppe AG recently received in-principle approval to open Julius Baer (Abu Dhabi) Ltd. in ADGM to serve ultra-high-net-worth clients and appointed long-time Goldman Sachs compliance leader Victoria McLean as its future Chief Compliance Officer and Executive Board member, completing a revamped risk and compliance structure. These moves point to a simultaneous push into a growing Middle Eastern wealth hub and a material strengthening of governance through a more independent, senior...

As European markets continue to show resilience, with the STOXX Europe 600 Index climbing 2.35% and major single-country indexes also posting gains, investors are increasingly looking toward dividend stocks as a stable income source amid subdued inflation rates across the eurozone. In this environment, selecting stocks that offer reliable dividend yields can be an effective strategy for those seeking consistent returns while navigating the current economic landscape.

Key Insights Barry Callebaut will host its Annual General Meeting on 10th of December CEO Peter Feld's total...

Wondering if Adecco Group is quietly offering value while the market looks the other way? Let us unpack what the numbers are really saying about the stock. The share price has slipped about 9.6% over the last week and is roughly flat over 1 year, which hints that sentiment is cautious even though the long term decline of around 45.1% over 5 years may already have washed out some optimism. Recent headlines have focused on Adecco's strategic moves to streamline operations and sharpen its focus...

As the pan-European STOXX Europe 600 Index and major single-country stock indexes continue to rise, investors are keeping a close eye on inflation trends that suggest eurozone inflation could remain near the European Central Bank's target. In this environment, growth companies with high insider ownership may capture attention due to their potential for aligning management interests with shareholder value, making them an intriguing focus for those navigating Europe's evolving market landscape.

As European markets experience a positive upswing, with the STOXX Europe 600 Index rising by 2.35%, investors are keenly observing the region's economic landscape, particularly as inflation appears to align closely with the European Central Bank’s target. In this context, dividend stocks can offer attractive opportunities for income-focused investors seeking stability and potential growth in a market characterized by subdued inflation and strategic fiscal adjustments.

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...